MedTrace Logo

Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC

NCT02893540 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2016-09-16

No results posted yet for this study

Summary

The optimum regimen of maintenance treatment after first-line chemotherapy in patients with metastatic colorectal cancer (mCRC) is unknown. This study was designed to determine the efficacy and safety of maintenance treatment with capecitabine metronomic chemotherapy versus conventional chemotherapy.

Conditions

Interventions

DRUG

Capecitabine

we are going to compare two maintenance treatment models with capecitabine in this study

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Yifeng Wang, MD · Shanghai Rui Jin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-12-31
Completion
2019-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02893540 on ClinicalTrials.gov